A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- AbbVie
- Study ID
- NCT03089944
- Phase
- PHASE3
- Status
- Completed
Conditions
- Hepatitis C Virus (HCV)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Glecaprevir/Pibrentasvir — DRUGTablet
Study Details
A Phase 3b, single arm, open-label, multicenter study in treatment naïve adults with chronic HCV infection and compensated cirrhosis to assess the safety of 8 weeks of treatment with glecaprevir/pibrentasvir and to demonstrate the efficacy of the sustained virologic response 12 weeks post dosing (SVR12) rates of 8 weeks of treatment with glecaprevir/pibrentasvir compared to the historical SVR12 rates of 12 weeks of treatment with glecaprevir/pibrentasvir.
Key Dates
- Start date
- Apr 28, 2017
- Status verified
- Jun 2020
- Primary completion
- Jul 31, 2019
- Completion
- Nov 8, 2019
Study Design
- Enrollment
- 343 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeksGlecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.
Primary Outcome Measure
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Hepatitis C Virus (HCV) Genotype (GT) 1,2,4,5 and 6-infected Participants in the Per Protocol (PP) Population [ Time Frame: 12 weeks after last dose of study drug ]
Locations (40)
Find similar trials in Phoenix, AZ
Related Studies
- Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process for Electronic Health Record SystemNot Yet Recruiting · University of Florida · Gainesville, Florida
- California MEPS HubRecruiting · University of California, Los Angeles · Oakland, California